424 related articles for article (PubMed ID: 19445107)
1. Regulation of human immunodeficiency virus-1 latency and its reactivation.
Verdin E
Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
[TBL] [Abstract][Full Text] [Related]
2. A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells.
Macías D; Oya R; Saniger L; Martín F; Luque F
Hum Gene Ther; 2009 Nov; 20(11):1259-68. PubMed ID: 19604078
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
[TBL] [Abstract][Full Text] [Related]
4. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
5. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
6. Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.
Tang X; Lu H; Dooner M; Chapman S; Quesenberry PJ; Ramratnam B
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618654
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of HIV-1 proviral latency.
Bisgrove D; Lewinski M; Bushman F; Verdin E
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):805-14. PubMed ID: 16207172
[TBL] [Abstract][Full Text] [Related]
8. The Molecular Basis for Human Immunodeficiency Virus Latency.
Mbonye U; Karn J
Annu Rev Virol; 2017 Sep; 4(1):261-285. PubMed ID: 28715973
[TBL] [Abstract][Full Text] [Related]
9. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
10. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
12. Barriers to HIV Cure.
Stein J; Storcksdieck Genannt Bonsmann M; Streeck H
HLA; 2016 Oct; 88(4):155-63. PubMed ID: 27620852
[TBL] [Abstract][Full Text] [Related]
13. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
Wang FX; Xu Y; Sullivan J; Souder E; Argyris EG; Acheampong EA; Fisher J; Sierra M; Thomson MM; Najera R; Frank I; Kulkosky J; Pomerantz RJ; Nunnari G
J Clin Invest; 2005 Jan; 115(1):128-37. PubMed ID: 15630452
[TBL] [Abstract][Full Text] [Related]
14. Underlying mechanisms of HIV-1 latency.
Romani B; Allahbakhshi E
Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
[TBL] [Abstract][Full Text] [Related]
15. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
Dhamija N; Rawat P; Mitra D
Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
[TBL] [Abstract][Full Text] [Related]
17. The multifactorial nature of HIV-1 latency.
Lassen K; Han Y; Zhou Y; Siliciano J; Siliciano RF
Trends Mol Med; 2004 Nov; 10(11):525-31. PubMed ID: 15519278
[TBL] [Abstract][Full Text] [Related]
18. A broad drug arsenal to attack a strenuous latent HIV reservoir.
Stoszko M; Ne E; Abner E; Mahmoudi T
Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
Suryawanshi P; Bagul R; Shete A; Thakar M
Front Immunol; 2021; 12():663919. PubMed ID: 33995393
[TBL] [Abstract][Full Text] [Related]
20. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
